biotech
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return potential in a...
5 months ago
Last Updated: 2 months ago
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
10 months ago
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
1 year ago
Here are a few big biopharma names on which Wall Street is growing more bearish.
1 year ago
A few big biopharma names were on the move Tuesday morning, and analysts were taking their shot at them.
1 year ago
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
1 year ago
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
1 year ago
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
1 year ago
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
1 year ago
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
1 year ago
Last Updated: 1 year ago
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
1 year ago
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
2 years ago
Last Updated: 2 years ago
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
2 years ago
Last Updated: 2 years ago
Here are five biotech stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny...
2 years ago
Last Updated: 2 years ago
These five super-aggressive biotech stocks are all rated Buy at well-known Wall Street firms and are suitable for very aggressive investors that have a high-risk tolerance.
2 years ago